Major Challenges in Rheumatology:
Will We Ever Treat Smarter, Instead of Just Harder?

Vasco C. Romão¹,² and João Eurico Fonseca¹,² *

¹Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Keywords: rheumatology, personalized medicine, stratification, rheumatoid arthritis, biomarkers

"[A reply to letters recommending remedies]: Dear Sir (or Madam): I try every remedy sent to me. I am now on No. 67. Yours is 2,653. I am looking forward to its beneficial results."

Mark Twain, quoted in My Father Mark Twain, by Clara Clemens

THE TREATMENT REVOLUTION IN RHEUMATOLOGY

The field of rheumatology has witnessed astonishing progress in the understanding and management of rheumatic diseases since the second half of the twentieth century. The discovery and introduction of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) into the therapeutic armamentarium of rheumatologists enabled, for the first time, to effectively change the natural course of disease and improve most clinical outcomes (1). The new millennium pushed the revolution further at an exponential level with the advent of sophisticated, biologically-engineered drugs—the so-called biologicals or bDMARDs—that targeted specific molecules in key pathogenic pathways and dramatically modified the prognosis of most patients with immune-mediated rheumatic diseases (2).

This progress, which was driven by tremendous research efforts to better understand the complex mechanisms behind each disease, has been particularly remarkable in inflammatory joint diseases such as rheumatoid arthritis (RA) and spondyloarthritis (including ankylosing spondylitis and psoriatic arthritis), and slower in the area of connective tissue diseases (e.g., systemic lupus erythematosus, Sjögren’s syndrome) and vasculitis. Indeed, as of March 2019, 10 original bDMARDs with 5 different mechanisms of action are approved in Europe for the treatment of RA, 9 for psoriatic arthritis (4 mechanisms of action), 6 for ankylosing spondylitis (2 mechanisms of action), only 1 for systemic lupus erythematosus and small-vessel vasculitis and none for Sjögren’s syndrome (3).

Yet, despite these significant advances, major unmet needs endure. The case of RA is paradigmatic of the current challenges faced by rheumatologists and patients alike in daily clinical practice. While at first, and especially when paralleled to other rheumatic diseases, RA seems to be the lucky relative of the rheumatology family with a variety of innovative bDMARDs available for treating and modifying the disease and improving patients’ lives and outcomes, in practice the reality is more complex (4, 5).

"ME-TOO" DRUGS AND THE TRIAL AND ERROR APPROACH

Firstly, after the major breakthroughs shown around the turn of the millennium by the pioneer bDMARDs approved for RA (infliximab and etanercept) in comparison to the standard of care...
available at the time (csDMARDs), the following decade observed a surge of other drugs that demonstrated a comparable effect in similar populations of patients (6). With a few exceptions (e.g., tocilizumab and sarilumab exhibiting superiority over methotrexate in monotherapy), new coming therapies usually conveyed a “me-too” effect that though important to increase treatment options in the event of inefficacy or intolerance, did not generate as tremendous an impact as its predecessors (7).

Secondly, the wide diversity of bDMARDs and modes of action contrasts with the profound lack of reliable, reproducible clinical and biological markers to inform treatment selection. Indeed, in spite of all the notable progress seen so far, we are somewhat surprisingly unable to recognize beforehand which individual patients will benefit more from a given drug, which will not respond at all and which are at a higher risk of toxicity or intolerance (8). Taking the specific example of RA, it should be acknowledged that there are a few well-established prognostic indicators that are associated at a group level with treatment-resistant disease, including female gender, older age, long lasting disease, failure of previous biologics, smoking, and high baseline disability (8, 9). But these features seem to be generically associated with worse treatment outcomes as a whole, rather than constituting specific predictors of response to a given drug. A couple of exceptions exist, such as the role of rheumatoid factor / anti-citrullinated protein antibodies seropositivity in determining a better response to rituximab (10) and abatacept (11) but also here this is a group effect and some seronegative patients will still show improvement with these treatments, while other seropositive patients will not experience any benefit. Other variables such as relevant comorbidities (e.g., lymphoma or monoclonal gammopathy) or infectious risk may further concede slight preference of one bDMARD over another and thus aid in the treatment decision process (12, 13), although again this is not driven by a particularly strong factor that identifies the best treatment for a given patient. This current landscape has inevitably led to the so-called trial and error approach that is the hallmark of present treatment strategies in RA and other inflammatory joint diseases and which has significant implications in terms of cost, risk and, ultimately, outcome.

**LIMITATIONS OF PRESENT TREATMENT MODALITIES**

Undeniably, coupled with the major benefits brought by these therapies, a few shortcomings have emerged. These are powered by the aforementioned unprecise treatment paradigm, with implications both at the patient and societal level. The first factor is related to the significant direct costs associated with these drugs, which has put additional financial pressure in already struggling healthcare systems (14). However, it has been shown that the overall cost associated with RA management has not increased significantly over the last decades, due to a major drop in indirect costs and productivity losses that compensated for the higher drug-related expenditure (14, 15). In fact, the main concern is that lacking robust personalized treatment strategies, patients may be treated with costly bDMARDs for an extended period of time without experiencing any relevant benefit but still be exposed to its risks and potential adverse events. It is remarkable that in such a case, the risk-benefit ratio is clearly tilted in the wrong direction, and yet, health authorities, physicians and patients, all seem to ignore or accept this fact as inevitable.

Currently, bDMARDs have a well-established safety profile (16), that needs to be balanced against the corresponding benefits provided by the treatment itself. A number of serious conditions—such as tuberculosis and other serious infections or liver and medullary toxicity, to name just a few (17)—are associated with bDMARDs and are accepted only in return for substantial efficacy and improvement of short- and long-term outcomes. If this second part of the equation is missing, as is the case of the considerable proportion of patients that fail to see any benefit at all, it may be ethically (and financially, as explained above) unacceptable to prescribe and administer these drugs. Hence, the problem relies in the fact that we are unable to identify these patients beforehand, emphasizing the limitations of this treatment model and the need for an individualized approach. The scenario is aggravated when we also take into account the short-term, highly-intensive, remission-inducing regimens that are applied in several rheumatic diseases, usually with substantial toxicity, in an indiscriminate manner (18–20). These treatment modalities represent the standard of care, but personalized treatment could revolutionize the current paradigm of an all-or-nothing approach simply based on the existence of a certain diagnosis.

Another aspect that should be considered when analyzing the issue of undiscerning drug selection is effective treatment delay. Treat-to-target (T2T) approaches have shown that, in terms of prognosis, more important than the drug administered is the therapeutic target defined and the quickness to attain it (21, 22). Subjecting patients to treatments that will not be effective for long periods—at least 3 to 6 months as per standard recommendations (23)—will cost precious time during which disease activity is high and structural damage readily occurs. This leads to poor long-term outcomes and is yet another reason for why a generalized same-drug-for-all strategy is flawed. The discovery of precise biomarkers of response to inform treatment selection could save up this lost time and, thus, synergistically reinforce the T2T strategy. In spite of this, T2T advocates have, somewhat surprisingly, disregarded the importance of personalized medicine vs. the main goal of abating disease activity regardless of the mechanism implied and drug chosen (24). However, as they point out, this only reflects the current standing, where precise biomarkers that have a major impact on treatment selection and can modify and guide clinical practice are still missing (8, 25).

Importantly, one should not forget other additional factors contributing to treatment limitations. Despite major improvements in the area of early diagnosis, it has recently been reported that in daily clinical practice the reality is still far from optimal (26–28). Moreover, there has also been a continuous global effort for the development and update of classification criteria of rheumatic diseases, but these are aimed at patient recruitment in research studies, in most cases perform poorly...
in a real-world setting, and therefore should not be applied for clinical diagnosis (29). Finally, with the incorporation into routine care of highly sensitive diagnostic techniques such as ultrasonography or magnetic resonance imaging, the concern of overdiagnosis and overtreatment of rheumatic diseases is already a reality, that should be addressed (30). These aspects allow to better understand the delicate landscape in which drugs are prescribed and underscore the need to improve treatment approaches.

NEW PLAYERS: THE ROLE OF BIOSIMILARS AND NOVEL TARGETED SYNTHETIC MOLECULES

As we have exposed, currently available bDMARDs compose an heterogeneous group of drugs, with several modes of action, distinct dosages, schedules, and routes of administration and some particularities in terms of concomitant medication, monitoring, or adverse events. However, the overall efficacy and safety between bDMARDs is considered to be roughly similar and long-term outcomes of patients treated with these drugs are not substantially different (2, 7). For this matter, we should highlight the importance of disease registers, both national and international, which have greatly contributed to demonstrate the benefits and pitfalls of treatments in a real-life setting (31).

It is in this setting that in the last 5–10 years two new treatment classes have appeared to add to the complexity of rheumatic patients management: biosimilar DMARDs (bsDMARDs or biosimilars) and targeted synthetic DMARDs (tsDMARDs). Both have contributed to widen the options available for treating RA patients, but also brought along additional challenges to the table.

Biosimilars emerged following the patent expiry of bDMARDs and promised to increase patient access by significantly decreasing treatment costs while, simultaneously, showing comparable efficacy and safety (32, 33). Following rigorous clinical trial programs demonstrating equivalence to the original bDMARDs, there are currently 16 bsDMARDs approved in Europe for the treatment of RA (4 infliximab, 3 etanercept, 6 adalimumab, 3 rituximab), with others awaiting approval (2 adalimumab), already withdrawn (2 adalimumab) or not having applied for RA indication (3 rituximab) (3). These impressive numbers speak well to the potential impact of bsDMARDs in the field. Indeed, its main added value relies in the reduced cost—20 to 40% below reference bDMARDs, depending on country—and, consequently, the larger number of patients that can be treated with these drugs (33, 34). While this partially resolves one of the issues mentioned above (cost), the other two (safety and time lost) remain unchanged. Ultimately, the increase in offer could even amplify the problem, with patients switching often between different bDMARDs and bsDMARDs in the pursuit of the right drug, with the associated implications in treatment delay and pharmacovigilance issues. This further reinforces the need for patient stratification and rational treatment selection.

Nonetheless, bsDMARDs have undoubtedly opened a new era in the treatment of rheumatic diseases. Rates of first bsDMARD are rising in Europe (34), and after the main pivotal trials, good quality observational data have confirmed the safety of switching patients from the original drug to its biosimilar (35–37). Concurrently, other challenges arise, such as selection and switching between biosimilars of the same bDMARD, different immunogenicity patterns and, potentially, lack of evidence for established prognosis markers that may differ from those known for the original drug (35, 36). This latter aspect may be fueled by a low willingness of bsDMARD drug developers to better explore disease heterogeneity, as this could potentially be commercially unattractive and limit the promotion of these drugs. Additionally, the nocebo effect—the negative effect of a treatment that is attributable to poor patient expectations—is a well-defined phenomenon that is particularly troublesome when switching real-world patients from original bDMARDs to bsDMARDs, due to the importance played by subjective measures (e.g., pain and global assessment, tender joint counts) in the evaluation of disease activity and treatment response (38).

A novel class of oral highly specific small molecules inhibiting intracellular signaling pathways, the tsDMARDs, has also become available (39). Tofacitinib, a Janus kinase inhibitor approved in the United States (2012) and Europe (2017), was recently followed by baricitinib (2018 and 2017, respectively) as the first two oral drugs that have an efficacy and safety profile comparable to bDMARDs (40). This is a major advance, given the preference of many patients for oral vs. parenteral administration. Other potential advantages include rapid clinical efficacy, even in monotherapy, absence of immunogenicity and a shorter half-life, facilitating the management of adverse drug reactions (39, 40). However, its place in treatment algorithms (before or after cs/b/bsDMARDs) is still to be fully understood. Most importantly, while tsDMARDs will definitely be beneficial for a large number of patients, the lack of predictive biomarkers precludes its rational application at the individual patient level and its introduction in the clinical armamentarium follows the same trial and error approach.

THE LAG OF PERSONALIZED MEDICINE IN RHEUMATOLOGY

A number of reasons can be put forward as to why personalized medicine is taking a long time to materialize in rheumatology. First, the heterogeneous and multifactorial nature of immune-mediated rheumatic diseases, with complex pathogenesis, makes it unlikely that a single marker of a given pathway will discriminate response of several different DMARDs with contrasting modes of action (41). Second, a considerable amount of effort is dedicated to identifying biomarkers in the blood, far from the key immunopathologic events happening at the synovial tissue, which may prove more informative (42). Third, one aspect that is not so commonly cited relates to the subjective nature of a significant part of the tools used to assess treatment response, remission status or disability. This applies both to the patient (e.g., visual analog scale) and the physician (e.g., joint counts) and is, by definition, influenced by many other individual-related factors, such as personality, previous experience with a given drug, expectations, patient-doctor relationship, cultural context,
In summary, the present moment in rheumatology is an exciting one, after two fast-paced decades that transformed the prognosis of patients with inflammatory rheumatic diseases. This was mainly due to a deep expansion of available, effective therapies that have come, nonetheless, coupled with major challenges that need to be tackled. We argue that this is the time to do so, where research efforts should be best directed at establishing robust biomarker-based treatment models that will allow individualized care. If successful, the outcome of this approach is likely to translate into more substantial benefits, compared to the meek pursuit of new drugs—often with the same or close mechanisms of action—that will provide a similar overall effect to currently available options. Synovial tissue should be at the center of these investigations, as targeting the disease process at its core will arguably prove most valuable. This is definitely a sinuous path, not without many expectable setbacks, but one worth tracking as its completion may finally lead to a new longed-for era of personalized medicine in rheumatology. Notably, despite all the cutting-edge science behind these innovations, clinical expertise of rheumatologists will be of strategic importance in guiding the process along the way.

**AUTHOR CONTRIBUTIONS**

VR and JF contributed to manuscript conception and design, literature review, manuscript preparation, and critical review. Both authors have read and approved the final version of the manuscript.

**FUNDING**

VR’s work was partially supported by Fundação para a Ciência e Tecnologia (Internos Doutorando Bursary reference SFRH/SINTD/95030/2013).

**REFERENCES**

1. Aggarwal D, Abraham S. Rheumatoid arthritis treatments: a historical perspective. *JSM Arthritis*. (2016) 1:1011.
2. Conti F, Cecarelli F, Massaro L, Cipriano E, Franco M D, Alessandri C, et al. Biological therapies in rheumatic diseases. *Clin Ter*. (2013) 164:413–28. doi: 10.7417/CT.2013.1622
3. European Medicines Agency. Available: https://www.ema.europa.eu/en/search/search (cited Mar 31, 2019).
4. Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. *Ann Rheum Dis*. (2019) 20:1–7. doi: 10.1136/annrheumdis-2018-214280
5. van Vollenhoven RF. Unresolved issues in biologic therapy for rheumatoid arthritis. *Nat Rev Rheumatol*. (2011) 7:205–15. doi: 10.1038/nrrheum.2011.22
6. Avci AB, Feist E, Burmester G-R. Biologicals in rheumatoid arthritis: current and future. *RMD Open*. (2015) 1:x000127. doi: 10.1136/rmdopen-2015-000127
7. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. *Lancet*. (2017) 389:2338–48. doi: 10.1016/S0140-6736(17)31491-5
8. Romão VC, Vital EM, Fonseca JE, Buch MH. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? *Arthritis Res Ther*. (2017) 19:239. doi: 10.1186/s13075-017-1445-3
9. Wijbrandts CA, Tak PP. Prediction of response to targeted treatment. *Mayo Clin Proc*. (2017) 92:1129–43. doi: 10.1016/j.mayocp.2017.05.009
10. Isaacs JD, Cohen SR, Emery P, Tak PP, Wang J, Lee G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. *Ann Rheum Dis*. (2012) 72:329–36. doi: 10.1136/annrheumdis-2011-201117
11. Gottenberg JE, Courvoisier DS, Hernandez M V, Iannone F, Lie E, Canhão H, et al. Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European Registry Analysis. *Arthritis Rheumatol*. (2016) 68:1346–52. doi: 10.1002/art.39595
12. Monti S, Klerry C, Gorla R, Sarzi-puttini P, Atzeni F, Pellerito R, et al. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. *Clin Rheumatol*. (2017) 36:753–61. doi: 10.1007/s10067-016-3528-y
13. Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? *Arthritis Res Ther*. (2016) 18:282. doi: 10.1186/s13075-016-1176-x
14. Huscher D, Mittendorf T, von Hinüber U, Kötter I, Hoese G, Pfäfflin A, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. *Ann Rheum Dis*. (2015) 74:738–45. doi: 10.1136/annrheumdis-2013-204311
15. Kalkan A, Hallert E, Bemfort L, Husberg M, Carlsson P. Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in Sweden. *Rheumatol*. (2014) 53:153–60. doi: 10.1093/rheumatology/ket290
16. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. *Nat Rev Rheumatol*. (2011) 7:639–52. doi: 10.1038/nrrheum.2011.145
17. Ramiro S, Sepriano A, Chatzidiakouzi K, Nam JI, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis*. (2017) 76:1101–36. doi: 10.1136/annrheumdis-2016-210708
18. Mok CC. Con: cyclophosphamide for the treatment of lupus nephritis. *Nephrol Dial Transplant*. (2016) 31:1053–7. doi: 10.1093/ndt/gfw068
19. King C, Harper L. Avoidance of harm from treatment for ANCA-associated vasculitis. *Curr Treat Options Rheumatol*. (2017) 3:230–43. doi: 10.1007/s40674-017-0082-y
20. Espinoza F, Fabre S, Pers YM. Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. *Ther Adv Musculoskelet Dis*. (2016) 8:107–18. doi: 10.1177/1759720X16654476
21. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*. (2016) 75:13–15. doi: 10.1136/annrheumdis-2015-207524
22. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. *Ann Rheum Dis*. (2016) 75:16–22. doi: 10.1136/annrheumdis-2015-207526
23. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidiakouzi K, Dougados M, et al. EULAR recommendations for the management
of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis.* (2017) 76:960–77. doi: 10.1136/annrheumdis-2016-210715

24. Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. *Ann Rheum Dis.* (2013) 72:3–6. doi: 10.1136/annrheumdis-2012-202361

25. Cuppen BVI, Welsing PML, Sprengers JJ, Bijlsma JWJ, Marijnissen ACA, van Laar JM, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. *Rheumatol.* (2016) 55:826–39. doi: 10.1093/rheumatology/kew421

26. Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, et al. Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. *Rheumatol.* (2018) 57:813–7. doi: 10.1093/rheumatology/kex504

27. Sørensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. *Ann Rheum Dis.* (2015) 74:1–7. doi: 10.1136/annrheumdis-2013-204867

28. Stack RJ, Nightingale P, Jinks C, Shaw K, Herron-Marx S, Horne R, et al. Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study. *BMJ Open.* (2019) 9:1–8. doi: 10.1136/bmjopen-2018-024361

29. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Overdiagnosis and overtreatment in rheumatology: The Impact of Biosimilar Competition in Europe. *Curr Rheumatol Rep* (2019). doi: 10.1080/14712598.2019.1610381. [Epub ahead of print].

30. Landewé RBM. Overdiagnosis and overtreatment in rheumatology: a little caution is in order. *Ann Rheum Dis.* (2018) 77:1394–6. doi: 10.1136/annrheumdis-2018-213700

31. Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: Methodological aspects, current role and future applications. *Nat Rev Rheumatol.* (2017) 13:503–10. doi: 10.1038/nrrheum.2017.81

32. Dörner T, Strand V, Cornes P, Gonzalves J, Gulácsi L, Kay J, et al. The changing landscape of biologicals in rheumatology. *Ann Rheum Dis.* (2016) 75:974–82. doi: 10.1136/annrheumdis-2018-213700

33. Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? *Curr Rheumatol Rep.* (2016) 18:50. doi: 10.1007/s11926-016-0601-0

34. IQVIA. The Impact of Biosimilar Competition in Europe. (2018) Available online at: https://ec.europa.eu/docsroom/documents/31642/attachments/1?translations=en/renditions/native

35. Edwards CJ, Hercogová J, Albrand H, Amiot A. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. *Expert Opin Biol Ther.* (2019). doi: 10.1080/14712398.2019.1610381. [Epub ahead of print].

36. Toussriot E, Marotte H. Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? *RMD Open.* (2017) e000492. doi: 10.1136/rmdopen-2017-000492

37. Kay J, Schools MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. *Ann Rheum Dis.* (2018) 77:165–74. doi: 10.1136/annrheumdis-2017-211937

38. Glinborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. *Ann Rheum Dis.* (2019) 78:192–200. doi: 10.1136/annrheumdis-2018-213474

39. Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. *Immunotherapy.* (2019) 11:737–54. doi: 10.2217/imt-2018-0178

40. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. *Rheumatol.* (2019) 58(Suppl. 1):i17–26. doi: 10.1093/rheumatology/key225

41. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. *Lancet.* (2017) 389:2328–37. doi: 10.1016/S0140-6736(17)31472-1

42. Astorri E, Nerviani A, Bombardieri M, Pitzalis C. Towards a Stratified Targeted Approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology. *Carr Pharm Des.* (2015) 21:2216–24. doi: 10.2174/1381612821666150310145758

43. Hammer HB, Uhlig T, Kvien TK, Lampä J. Pain Catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. *Arthritis Care Res.* (2018) 70:703–12. doi: 10.1002/acr.23339

44. Dougdos M, Nataf H, Steinberg G, Rouanet S, Falissard B. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. *Rheumatol.* (2013) 52:391–9. doi: 10.1093/rheumatology/kes285

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Romão and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.